AORT ARTIVION, INC.
NYSE · SEC CIK 784199 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $20.73M 46 sales by 8 insiders
- Filings on record
- 315 since 2021-08-24, latest 2026-09-11 17:28
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Mackin James P | Pres, CEO | — | $9.72M |
| Stanton Marshall S. | SVP, Clinical, MD Affair | — | $3.43M |
| Holloway Jean F | SVP, GC | — | $2.54M |
| Davis John E | Chief Commercial Off | — | $1.75M |
| GREEN ANDREW M | SVP, Regulatory, Quality | — | $1.43M |
| Horton Amy | VP, CAO | — | $870.1K |
| Berry Lance A | EVP, COO, CFO, Treas | — | $803.2K |
| Hoff Elizabeth A | Dir | — | $189.4K |
| SEMEDO ANTHONY B. | Dir | — | — |
| Borgstrom Marna P | Dir | — | — |
Transactions 430
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-11 17:28 | 2026-09-10 | AORT | GREEN ANDREW M | SVP, Regulatory, Quality | S - Sale | $24.97 | -11.5K | 40.2K | -22% | -$286.7K | |
| M | 2026-09-04 14:15 | 2026-09-02+ | AORT | GREEN ANDREW M | SVP, Regulatory, Quality | S - Sale | $27.03 | -8,003 | 51.6K | -13% | -$216.3K |
| 2026-08-20 14:11 | 2026-08-19 | AORT | Mackin James P | Pres, CEO | S - Sale | $28.95 | -70.0K | 877.3K | -7% | -$2.03M | |
| 2026-08-17 15:18 | 2026-08-14 | AORT | GREEN ANDREW M | SVP, Regulatory, Quality | S - Sale | $28.55 | -616 | 59.6K | -1% | -$17.6K | |
| 2026-08-17 15:17 | 2026-08-14 | AORT | Berry Lance A | EVP, COO, CFO, Treas | S - Sale | $28.55 | -715 | 210.1K | -0.3% | -$20.4K | |
| 2026-08-12 17:51 | 2026-08-12 | AORT | Holloway Jean F | SVP, GC | S - Sale | $28.49 | -977 | 184.1K | -0.5% | -$27.8K | |
| DMT | 2026-06-15 11:28 | 2026-06-11 | AORT | GREEN ANDREW M | SVP, Regulatory, Quality | M - OptEx | $13.39 | +44.0K | 90.3K | +95% | +$589.1K |
| DMT | 2026-06-15 11:28 | 2026-06-11 | AORT | GREEN ANDREW M | SVP, Regulatory, Quality | S - Sale+OE | $20.70 | -44.0K | 60.3K | -42% | -$910.7K |
| 2026-06-04 16:50 | 2026-06-02 | AORT | SEMEDO ANTHONY B. | Dir | J - Other | $0.00 | -6,325 | 40.6K | -13% | $0 | |
| I | 2026-06-04 16:50 | 2026-06-02 | AORT | SEMEDO ANTHONY B. | Dir | J - Other | $0.00 | +6,325 | 6,325 | New | $0 |
| A | 2026-05-20 21:15 | 2026-05-18 | AORT | Borgstrom Marna P | Dir | A - Grant | $0.00 | +7,576 | 56.7K | +15% | $0 |
| 2026-05-20 20:37 | 2026-05-18 | AORT | SEMEDO ANTHONY B. | Dir | A - Grant | $0.00 | +7,576 | 47.0K | +19% | $0 | |
| 2026-05-20 20:35 | 2026-05-18 | AORT | Salveson Jon W | Dir | A - Grant | $0.00 | +7,576 | 137.4K | +6% | $0 | |
| 2026-05-20 20:33 | 2026-05-18 | AORT | Hoff Elizabeth A | Dir | A - Grant | $0.00 | +7,576 | 34.8K | +28% | $0 | |
| 2026-05-20 20:32 | 2026-05-18 | AORT | Burbank Jeffrey H | Dir | A - Grant | $0.00 | +7,576 | 61.4K | +14% | $0 | |
| 2026-05-20 20:30 | 2026-05-18 | AORT | Bullock James | Dir | A - Grant | $0.00 | +7,576 | 76.2K | +11% | $0 | |
| 2026-05-20 20:28 | 2026-05-18 | AORT | BEVEVINO DANIEL J | Dir | A - Grant | $0.00 | +7,576 | 157.6K | +5% | $0 | |
| 2026-05-20 20:26 | 2026-05-18 | AORT | ACKERMAN THOMAS F | Dir | A - Grant | $0.00 | +7,576 | 157.5K | +5% | $0 | |
| 2026-05-19 21:59 | 2026-05-14 | AORT | Borgstrom Marna P | Dir | A - Grant | $0.00 | +7,850 | 56.9K | +16% | $0 | |
| 2026-03-04 | 2026-03-03 | AORT | Davis John E | Chief Commercial Off | S - Sale | $37.78 | -4,573 | 230.8K | -2% | -$172.8K | |
| 2026-03-04 | 2026-03-02 | AORT | Davis John E | Chief Commercial Off | A - Grant | $0.00 | +28.8K | 235.4K | +14% | $0 | |
| 2026-03-04 | 2026-03-02 | AORT | Horton Amy | VP, CAO | A - Grant | $0.00 | +7,475 | 140.0K | +6% | $0 | |
| 2026-03-04 | 2026-03-03 | AORT | Horton Amy | VP, CAO | S - Sale | $37.78 | -901 | 139.1K | -0.6% | -$34.0K | |
| 2026-03-04 | 2026-03-02 | AORT | Holloway Jean F | SVP, GC | A - Grant | $0.00 | +27.8K | 197.9K | +16% | $0 | |
| M | 2026-03-04 | 2026-03-03+ | AORT | Holloway Jean F | SVP, GC | S - Sale | $37.93 | -12.8K | 185.1K | -6% | -$485.7K |
| 2026-03-04 | 2026-03-02 | AORT | Berry Lance A | EVP, COO, CFO, Treas | A - Grant | $0.00 | +40.9K | 217.1K | +23% | $0 | |
| 2026-03-04 | 2026-03-03 | AORT | Berry Lance A | EVP, COO, CFO, Treas | S - Sale | $37.78 | -6,316 | 210.8K | -3% | -$238.6K | |
| 2026-03-04 | 2026-03-02 | AORT | Mackin James P | Pres, CEO | A - Grant | $0.00 | +116.9K | 965.2K | +14% | $0 | |
| 2026-03-04 | 2026-03-03 | AORT | Mackin James P | Pres, CEO | S - Sale | $37.78 | -17.9K | 947.3K | -2% | -$675.8K | |
| 2026-03-04 | 2026-03-02 | AORT | Stanton Marshall S. | SVP, Clinical, MD Affair | A - Grant | $0.00 | +21.8K | 62.2K | +54% | $0 | |
| 2026-03-04 | 2026-03-03 | AORT | Stanton Marshall S. | SVP, Clinical, MD Affair | S - Sale | $37.78 | -2,149 | 60.1K | -3% | -$81.2K | |
| 2026-03-03 | 2026-03-02 | AORT | Holloway Jean F | SVP, GC | S - Sale | $38.02 | -2,183 | 170.1K | -1% | -$83.0K | |
| 2026-03-03 | 2026-03-02 | AORT | Davis John E | Chief Commercial Off | S - Sale | $38.02 | -2,784 | 206.5K | -1% | -$105.8K | |
| 2026-03-03 | 2026-03-02 | AORT | Horton Amy | VP, CAO | S - Sale | $38.02 | -641 | 132.5K | -0.5% | -$24.4K | |
| 2026-03-03 | 2026-03-02 | AORT | Berry Lance A | EVP, COO, CFO, Treas | S - Sale | $38.02 | -5,178 | 176.3K | -3% | -$196.9K | |
| 2026-03-03 | 2026-03-02 | AORT | Mackin James P | Pres, CEO | S - Sale | $38.02 | -14.9K | 848.2K | -2% | -$566.9K | |
| 2026-03-03 | 2026-03-02 | AORT | Stanton Marshall S. | SVP, Clinical, MD Affair | S - Sale | $38.02 | -1,513 | 40.4K | -4% | -$57.5K | |
| M | 2026-02-25 | 2026-02-23+ | AORT | Mackin James P | Pres, CEO | S - Sale | $36.83 | -34.9K | 766.1K | -4% | -$1.29M |
| 2026-02-25 | 2026-02-24 | AORT | Mackin James P | Pres, CEO | A - Grant | $0.00 | +97.0K | 863.1K | +13% | $0 | |
| M | 2026-02-25 | 2026-02-23+ | AORT | Berry Lance A | EVP, COO, CFO, Treas | S - Sale | $36.69 | -9,466 | 144.0K | -6% | -$347.3K |
| 2026-02-25 | 2026-02-24 | AORT | Berry Lance A | EVP, COO, CFO, Treas | A - Grant | $0.00 | +37.5K | 181.4K | +26% | $0 | |
| M | 2026-02-25 | 2026-02-23+ | AORT | Holloway Jean F | SVP, GC | S - Sale | $36.92 | -4,747 | 152.2K | -3% | -$175.3K |
| 2026-02-25 | 2026-02-24 | AORT | Holloway Jean F | SVP, GC | A - Grant | $0.00 | +20.1K | 172.3K | +13% | $0 | |
| M | 2026-02-25 | 2026-02-23+ | AORT | Horton Amy | VP, CAO | S - Sale | $36.97 | -2,561 | 128.3K | -2% | -$94.7K |
| 2026-02-25 | 2026-02-24 | AORT | Horton Amy | VP, CAO | A - Grant | $0.00 | +5,658 | 133.2K | +4% | $0 | |
| M | 2026-02-25 | 2026-02-23+ | AORT | Davis John E | Chief Commercial Off | S - Sale | $36.92 | -5,848 | 190.9K | -3% | -$215.9K |
| 2026-02-25 | 2026-02-24 | AORT | Davis John E | Chief Commercial Off | A - Grant | $0.00 | +20.4K | 209.3K | +11% | $0 | |
| M | 2026-02-25 | 2026-02-23+ | AORT | Stanton Marshall S. | SVP, Clinical, MD Affair | S - Sale | $36.94 | -3,682 | 41.9K | -8% | -$136.0K |
| 2025-12-17 | 2025-12-15 | AORT | Davis John E | Chief Commercial Off | S - Sale | $45.11 | -5,000 | 193.8K | -3% | -$225.6K | |
| 2025-12-09 | 2025-12-08 | AORT | Horton Amy | VP, CAO | S - Sale | $44.42 | -4,572 | 130.1K | -3% | -$203.1K | |
| D | 2025-12-04 | 2025-12-03 | AORT | Mackin James P | Pres, CEO | S - Sale+OE | $45.46 | -30.9K | 801.0K | -4% | -$1.41M |
| D | 2025-12-04 | 2025-12-03 | AORT | Mackin James P | Pres, CEO | M - OptEx | $29.62 | +30.9K | 831.9K | +4% | +$915.9K |
| M | 2025-12-04 | 2025-12-03 | AORT | Holloway Jean F | SVP, GC | S - Sale | $45.30 | -7,315 | 156.1K | -4% | -$331.4K |
| D | 2025-12-03 | 2025-12-02 | AORT | Mackin James P | Pres, CEO | S - Sale+OE | $45.56 | -30.9K | 801.0K | -4% | -$1.41M |
| D | 2025-12-03 | 2025-12-02 | AORT | Mackin James P | Pres, CEO | M - OptEx | $29.62 | +30.9K | 831.9K | +4% | +$915.9K |
| 2025-12-02 | 2025-12-01 | AORT | Horton Amy | VP, CAO | G - Gift | $0.00 | -750 | 134.6K | -0.6% | $0 | |
| DM | 2025-11-24 | 2025-11-21 | AORT | Stanton Marshall S. | SVP, Clinical, MD Affair | S - Sale+OE | $45.04 | -47.4K | 44.8K | -51% | -$2.13M |
| DM | 2025-11-24 | 2025-11-21 | AORT | Stanton Marshall S. | SVP, Clinical, MD Affair | M - OptEx | $14.21 | +47.4K | 71.8K | +194% | +$673.0K |
| DM | 2025-11-24 | 2025-11-20 | AORT | Stanton Marshall S. | SVP, Clinical, MD Affair | M - OptEx | $15.48 | +3,388 | 46.8K | +8% | +$52.4K |
| DM | 2025-11-24 | 2025-11-20 | AORT | Stanton Marshall S. | SVP, Clinical, MD Affair | S - Sale+OE | $44.18 | -15.3K | 44.8K | -25% | -$674.8K |
| 2025-11-19 | 2025-11-18 | AORT | Hoff Elizabeth A | Dir | S - Sale | $45.10 | -4,200 | 27.2K | -13% | -$189.4K | |
| DM | 2025-11-18 | 2025-11-14+ | AORT | Holloway Jean F | SVP, GC | M - OptEx | $29.62 | +12.8K | 169.8K | +8% | +$378.8K |
| DM | 2025-11-18 | 2025-11-14+ | AORT | Holloway Jean F | SVP, GC | S - Sale+OE | $45.09 | -12.8K | 163.4K | -7% | -$576.5K |
| DM | 2025-11-18 | 2025-11-14+ | AORT | Davis John E | Chief Commercial Off | S - Sale+OE | $44.92 | -12.8K | 198.8K | -6% | -$574.4K |
| DM | 2025-11-18 | 2025-11-14+ | AORT | Davis John E | Chief Commercial Off | M - OptEx | $29.62 | +12.8K | 205.2K | +7% | +$378.8K |
| 2025-11-18 | 2025-11-17 | AORT | Horton Amy | VP, CAO | S - Sale | $45.73 | -6,000 | 135.4K | -4% | -$274.4K | |
| 2025-11-14 | 2025-11-13 | AORT | Stanton Marshall S. | SVP, Clinical, MD Affair | S - Sale | $45.86 | -4,993 | 56.6K | -8% | -$229.0K | |
| 2025-11-14 | 2025-11-13 | AORT | Holloway Jean F | SVP, GC | S - Sale | $45.86 | -5,761 | 163.4K | -3% | -$264.2K | |
| 2025-11-14 | 2025-11-13 | AORT | Horton Amy | VP, CAO | S - Sale | $45.86 | -3,482 | 141.4K | -2% | -$159.7K | |
| 2025-11-14 | 2025-11-13 | AORT | Mackin James P | Pres, CEO | S - Sale | $45.86 | -34.2K | 801.0K | -4% | -$1.57M | |
| 2025-11-14 | 2025-11-13 | AORT | Davis John E | Chief Commercial Off | S - Sale | $45.86 | -6,563 | 198.8K | -3% | -$301.0K | |
| DM | 2025-11-12 | 2025-11-10+ | AORT | Holloway Jean F | SVP, GC | S - Sale+OE | $45.82 | -13.0K | 169.2K | -7% | -$593.9K |
| D | 2025-11-12 | 2025-11-11 | AORT | Holloway Jean F | SVP, GC | M - OptEx | $11.03 | +10.0K | 179.2K | +6% | +$110.3K |
| 2025-11-12 | 2025-11-10 | AORT | Davis John E | Chief Commercial Off | S - Sale | $44.62 | -3,373 | 205.4K | -2% | -$150.5K | |
| 2025-11-12 | 2025-11-10 | AORT | Stanton Marshall S. | SVP, Clinical, MD Affair | S - Sale | $44.62 | -2,566 | 61.6K | -4% | -$114.5K | |
| 2025-11-12 | 2025-11-10 | AORT | Horton Amy | VP, CAO | S - Sale | $44.62 | -1,789 | 144.9K | -1% | -$79.8K | |
| 2025-11-12 | 2025-11-10 | AORT | Mackin James P | Pres, CEO | S - Sale | $44.62 | -17.6K | 835.2K | -2% | -$784.4K | |
| D | 2025-08-28 | 2025-08-27 | AORT | Stanton Marshall S. | SVP, Clinical, MD Affair | M - OptEx | $11.03 | +18.2K | 82.4K | +28% | +$200.7K |
| D | 2025-08-28 | 2025-08-27 | AORT | Stanton Marshall S. | SVP, Clinical, MD Affair | S - Sale+OE | $44.02 | -18.2K | 64.2K | -22% | -$801.2K |
| D | 2025-08-26 | 2025-08-25 | AORT | Holloway Jean F | SVP, GC | M - OptEx | $11.03 | +10.0K | 182.1K | +6% | +$110.3K |
| D | 2025-08-26 | 2025-08-25 | AORT | Holloway Jean F | SVP, GC | S - Sale+OE | $44.37 | -10.0K | 172.1K | -5% | -$443.7K |
| 2025-08-19 | 2025-08-15 | AORT | Mackin James P | Pres, CEO | S - Sale | $42.32 | -12.5K | 852.8K | -1% | -$529.0K | |
| D | 2025-08-14 | 2025-08-12 | AORT | Davis John E | Chief Commercial Off | S - Sale+OE | $43.67 | -10.8K | 208.8K | -5% | -$471.7K |
| D | 2025-08-14 | 2025-08-12 | AORT | Davis John E | Chief Commercial Off | M - OptEx | $26.24 | +10.8K | 219.6K | +5% | +$283.4K |
| D | 2025-08-14 | 2025-08-12 | AORT | Holloway Jean F | SVP, GC | M - OptEx | $26.24 | +17.0K | 195.5K | +10% | +$445.4K |
| DM | 2025-08-14 | 2025-08-12 | AORT | Holloway Jean F | SVP, GC | S - Sale+OE | $43.01 | -23.4K | 178.5K | -12% | -$1.00M |
| D | 2025-08-11 | 2025-08-08 | AORT | Horton Amy | VP, CAO | S - Sale+OE | $38.49 | -7,992 | 146.7K | -5% | -$307.6K |
| D | 2025-08-11 | 2025-08-08 | AORT | Horton Amy | VP, CAO | M - OptEx | $29.62 | +7,992 | 154.6K | +5% | +$236.7K |
| M | 2025-06-18 | 2025-06-17 | AORT | Stanton Marshall S. | SVP, Clinical, MD Affair | S - Sale | $29.50 | -15.0K | 64.2K | -19% | -$442.5K |
| M | 2025-06-16 | 2025-06-13 | AORT | Stanton Marshall S. | SVP, Clinical, MD Affair | S - Sale | $28.44 | -26.1K | 79.2K | -25% | -$743.1K |
| 2025-05-27 | 2025-05-22 | AORT | SEMEDO ANTHONY B. | Dir | A - Grant | $0.00 | +6,325 | 42.0K | +18% | $0 | |
| 2025-05-27 | 2025-05-22 | AORT | Hoff Elizabeth A | Dir | A - Grant | $0.00 | +6,325 | 31.4K | +25% | $0 | |
| 2025-05-27 | 2025-05-23 | AORT | SEMEDO ANTHONY B. | Dir | S - Sale | $28.47 | -2,600 | 33.1K | -7% | -$74.0K | |
| A | 2025-05-27 | 2025-05-23 | AORT | SEMEDO ANTHONY B. | Dir | S - Sale | $28.47 | -2,600 | 39.4K | -6% | -$74.0K |
| 2025-05-27 | 2025-05-27 | AORT | Holloway Jean F | SVP, GC | S - Sale | $29.00 | -8,748 | 178.5K | -5% | -$253.7K | |
| 2025-05-27 | 2025-05-22 | AORT | Burbank Jeffrey H | Dir | A - Grant | $0.00 | +6,325 | 53.8K | +13% | $0 | |
| 2025-05-27 | 2025-05-22 | AORT | Borgstrom Marna P | Dir | A - Grant | $0.00 | +6,325 | 49.1K | +15% | $0 | |
| 2025-05-27 | 2025-05-22 | AORT | Salveson Jon W | Dir | A - Grant | $0.00 | +6,325 | 129.8K | +5% | $0 | |
| 2025-05-27 | 2025-05-22 | AORT | Bullock James | Dir | A - Grant | $0.00 | +6,325 | 68.6K | +10% | $0 | |
| 2025-05-27 | 2025-05-22 | AORT | BEVEVINO DANIEL J | Dir | A - Grant | $0.00 | +6,325 | 150.1K | +4% | $0 |
Purchase Sale Sale after option exercise All abbreviations